Skip to content

Taohong siwu decoction for arteriovenous fistula patency and use for hemodialysis: a randomized controlled trial

Taohong siwu decoction for arteriovenous fistula patency and use for hemodialysis: a randomized controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004530
Enrollment
Unknown
Registered
2021-03-06
Start date
2021-04-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal disease

Interventions

Control group:Placebo
PlaceboTHSWD

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with advanced chronic kidney disease and plan to initiate hemodialysis, and considering for fistula creation; 2. Aged >= 18 and <= 75 years, regardless of gender; 3. Agree to participate in this trial and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic or allergic to the ingredients of Taohong siwu decoction; 2. Patients who cannot cooperate with the use of medication for fistula; 3. The expected survival period is less than 1 year; 4. Those with serious underlying diseases, such as liver insufficiency, blood system disease, and coagulation dysfunction; 5. Arteriovenous fistula not created by the team of investigators.

Design outcomes

Primary

MeasureTime frame
AVF patency;AVF maturation;AVF abandonment;

Secondary

MeasureTime frame
AVF blood flow;

Countries

China

Contacts

Public ContactShisheng Han

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

hanss8612@163.com+86 13774380819

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026